The MMPE technology uses synergistic combinations of certain specific pharmaceutical excipients included on the FDA’s Inactive Ingredients Database (“IID”) for improved topical delivery of active ingredients into or through the skin.
MMPE™ boasts a unique combinations of FDA-approved excipients that provide enhanced delivery into or through the skin.
Increased penetration of active ingredients with possibility of improved efficacy.
Lower active ingredients concentration resulting in reduced dosing.
New formulations or slight modifications to existing formulations resulting in new IP.
Issued United States patents provide Intellectual Property (IP) protection until March 6, 2027.
Pending applications with latest expiry in 2036.